Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines
This article describes the pharmacology of approved parenteral anticoagulants. These
include the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight
heparins (LMWHs), fondaparinux, and danaparoid, as well as the direct thrombin inhibitors
hirudin, bivalirudin, and argatroban. UFH is a heterogeneous mixture of glycosaminoglycans
that bind to antithrombin via a unique pentasaccharide sequence and catalyze the
inactivation of thrombin, factor Xa, and other clotting enzymes. Heparin also binds to cells …
include the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight
heparins (LMWHs), fondaparinux, and danaparoid, as well as the direct thrombin inhibitors
hirudin, bivalirudin, and argatroban. UFH is a heterogeneous mixture of glycosaminoglycans
that bind to antithrombin via a unique pentasaccharide sequence and catalyze the
inactivation of thrombin, factor Xa, and other clotting enzymes. Heparin also binds to cells …
